Presentations, panels and moderated discussions across the four-day conference will span proven AI applications across the clinical trial lifecycle, real world evidence, risk-based quality management and patient-centered research
RALEIGH, N.C., June 11, 2026 (GLOBE NEWSWIRE) — Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry, will present during eight sessions at the 2026 Drug Information Association (DIA) Global Annual Meeting, taking place June 14-18, 2026, in Philadelphia. Company executives and subject matter experts will present, moderate and participate in panels about proven AI applications across the clinical trial lifecycle, real world evidence, risk-based quality management and patient-centered research.
Sessions featuring Parexel representatives are scheduled throughout the conference:
“DIA is a premier forum for advancing clinical development innovation, and Parexel is proud to showcase how AI, clinical trial innovation and human-centered approaches are transforming the industry,” said Keri Mattox, Chief Business & Strategy Officer, Parexel. “Our participation reflects Parexel’s commitment to research and thought leadership, and our dedication to accelerating the delivery of safe, effective therapies to patients worldwide.”
DIA is a global, multidisciplinary organization bringing together professionals across the entire spectrum of the life sciences industry. DIA serves as a neutral platform for knowledge exchange, fostering innovation and advancing global health through educational resources, conferences and collaboration among stakeholders.
Parexel will exhibit at Booth #1503 throughout the meeting. For more information about Parexel’s presence at DIA 2026 or to schedule a meeting with Parexel experts, visit Parexel Events.
About Parexel
Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart®. We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for “Innovative Approaches to Patient-Centric Research” and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow us on LinkedIn, X, Facebook and Instagram.
Media
Danaka Williams
+1 (984) 298 4207
Danaka.Williams@parexel.com
Addison Stallings
+1 (984) 833 6362
Addison.Stallings@parexel.com
See the complaint. When Commentary Becomes Advocacy? WASHINGTON, D.C. / ACCESS Newswire / June 13,…
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and…
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at…
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of…
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…